These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25846209)

  • 21. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.
    Cox LS; Casale TB; Nayak AS; Bernstein DI; Creticos PS; Ambroisine L; Melac M; Zeldin RK
    J Allergy Clin Immunol; 2012 Dec; 130(6):1327-34.e1. PubMed ID: 23122534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
    Kruse K; Gerwin E; Eichel A; Shah-Hosseini K; Mösges R
    J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Biedermann T; Kuna P; Panzner P; Valovirta E; Andersson M; de Blay F; Thrane D; Jacobsen SH; Stage BS; Winther L
    J Allergy Clin Immunol; 2019 Mar; 143(3):1058-1066.e6. PubMed ID: 30654054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season.
    van Hage-Hamsten M; Kronqvist M; Zetterström O; Johansson E; Niederberger V; Vrtala S; Grönlund H; Grönneberg R; Valenta R
    J Allergy Clin Immunol; 1999 Nov; 104(5):969-77. PubMed ID: 10550741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects.
    Ceuppens JL; Bullens D; Kleinjans H; van der Werf J;
    Clin Exp Allergy; 2009 Dec; 39(12):1903-9. PubMed ID: 20085600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant Bet v 1 vaccine for treatment of allergy to birch pollen.
    Grönlund H; Gafvelin G
    Hum Vaccin; 2010 Dec; 6(12):970-7. PubMed ID: 21157177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
    Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
    Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolerability of the SQ Tree SLIT Tablet in Adults.
    Birk AO; Andersen JS; Villesen HH; Steffensen MA; Calderon MA
    Clin Ther; 2017 Sep; 39(9):1858-1867. PubMed ID: 28844318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allergen immunotherapy for birch pollen-allergic patients: recent advances.
    Moingeon P; Floch VB; Airouche S; Baron-Bodo V; Nony E; Mascarell L
    Immunotherapy; 2016 May; 8(5):555-67. PubMed ID: 27140409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy.
    Baron-Bodo V; Horiot S; Lautrette A; Chabre H; Drucbert AS; Danzé PM; Sénéchal H; Peltre G; Galvain S; Zeldin RK; Horak F; Moingeon P
    Clin Exp Allergy; 2013 Dec; 43(12):1362-73. PubMed ID: 24261946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets.
    Malling HJ; Lund L; Ipsen H; Poulsen L
    J Investig Allergol Clin Immunol; 2006; 16(3):162-8. PubMed ID: 16784009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and immunological correlates of pre-co-seasonal sublingual immunotherapy with birch monomeric allergoid in patients with allergic rhinoconjunctivitis.
    Burastero SE; Mistrello G; Paolucci C; Breda D; Roncarolo D; Zanotta S; Falagiani P
    Int J Immunopathol Pharmacol; 2009; 22(2):343-52. PubMed ID: 19505388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant Bet v 1, the major birch pollen allergen, induces hypersensitivity reactions equal to those induced by natural Bet v 1 in the airways of patients allergic to tree pollen.
    Godnic-Cvar J; Susani M; Breiteneder H; Berger A; Havelec L; Waldhör T; Hirschwehr R; Valenta R; Scheiner O; Rüdiger H; Kraft D; Ebner C
    J Allergy Clin Immunol; 1997 Mar; 99(3):354-9. PubMed ID: 9058691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment Effect of the Tree Pollen SLIT-Tablet on Allergic Rhinoconjunctivitis During Oak Pollen Season.
    Nolte H; Waserman S; Ellis AK; Biedermann T; Würtzen PA
    J Allergy Clin Immunol Pract; 2021 May; 9(5):1871-1878. PubMed ID: 33548518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.
    Didier A; Malling HJ; Worm M; Horak F; Jäger S; Montagut A; André C; de Beaumont O; Melac M
    J Allergy Clin Immunol; 2007 Dec; 120(6):1338-45. PubMed ID: 17935764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population.
    Pauli G; Purohit A; Oster JP; De Blay F; Vrtala S; Niederberger V; Kraft D; Valenta R
    Clin Exp Allergy; 2000 Aug; 30(8):1076-84. PubMed ID: 10931114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Folded or Not? Tracking Bet v 1 Conformation in Recombinant Allergen Preparations.
    Husslik F; Hanschmann KM; Krämer A; Seutter von Loetzen C; Schweimer K; Bellinghausen I; Treudler R; Simon JC; Vogel L; Völker E; Randow S; Reuter A; Rösch P; Vieths S; Holzhauser T; Schiller D
    PLoS One; 2015; 10(7):e0132956. PubMed ID: 26186356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy.
    Bonvalet M; Moussu H; Wambre E; Ricarte C; Horiot S; Rimaniol AC; Kwok WW; Horak F; de Beaumont O; Baron-Bodo V; Moingeon P
    Clin Exp Allergy; 2012 Dec; 42(12):1745-55. PubMed ID: 23181790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1.
    Mahler V; Vrtala S; Kuss O; Diepgen TL; Suck R; Cromwell O; Fiebig H; Hartl A; Thalhamer J; Schuler G; Kraft D; Valenta R
    Clin Exp Allergy; 2004 Jan; 34(1):115-22. PubMed ID: 14720271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.